Compare WNC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | ALT |
|---|---|---|
| Founded | 1985 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.9M | 415.3M |
| IPO Year | 1991 | N/A |
| Metric | WNC | ALT |
|---|---|---|
| Price | $9.84 | $5.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.00 | ★ $16.00 |
| AVG Volume (30 Days) | 487.5K | ★ 6.4M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.15 | N/A |
| Revenue | ★ $1,638,115,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.16 | N/A |
| P/E Ratio | $1.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.78 | $2.90 |
| 52 Week High | $16.91 | $7.73 |
| Indicator | WNC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 56.64 |
| Support Level | $9.74 | $5.19 |
| Resistance Level | $10.16 | $6.36 |
| Average True Range (ATR) | 0.42 | 0.48 |
| MACD | -0.09 | 0.14 |
| Stochastic Oscillator | 14.19 | 46.98 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.